web analytics
0.4 C
Munich
Saturday, December 3, 2022

Anew Medical, Inc (OTCMKTS: LEAS) Big Move After Co Acquires Five Market-Approved Anti-Cancer Drugs Approved for Sale in Germany

Anew Medical, Inc (OTCMKTS: LEAS) is up big after the Company announced it has acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX” and “FOLFIRI” multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. 

Dr. Joseph Sinkule, the Founder and CEO of ANEW stated, “We will combine the oncology drugs and additional drug assets with a portfolio of biosimilar biologics also used in the treatment of cancer, and then grow the business with more additions to the portfolio. Initiating marketing and sales in Europe and then migrating the dossier to the US allows us time to build a reliable business franchise and gain name recognition both in Europe and then the US, the two major global pharmaceutical markets.


Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Anew Medical, Inc (OTCMKTS: LEAS) was formed to develop cutting-edge biologic medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. As we age and get older, these diseases become the major cause of death or disablement. There are two subsidiaries managed by the Anew Medical team – Anew Biologics, Inc. uses state-of-the-art biologic therapies to treat cancer – recombinant proteins made outside the body, and Anew Gene Therapies, Inc. uses a gene therapy approach to introduce therapeutic proteins inside the body – to either block factors causing disease or to replace human genes that have either shut down native protein production or have mutated to produce aberrant proteins that do not function at all. Anew Medical went public on November 1, 2021 via a reverse merger into Strategic Asset Leasing Inc. 

The Company has a two-pronged business strategy, “multiple shots-at-the –goal”, that it considers to be a “low risk/high risk” opportunity to investors. Anew Medical has licensed recombinant antibodies with known therapeutic activity and a known market (“low risk”) in treating cancer, autoimmune diseases, and vascular (eye) diseases, and these product candidates require a Phase 3 study and can be approved for marketing in the US and Europe (the major pharmaceutical markets) in three years. The antibodies are already approved in several countries outside of the US and EU markets. The Company has recently licensed gene therapy intellectual property from a renowned research institution in Barcelona, Spain that has shown the potential to halt or eliminate or stop the progression of Alzheimer’s Disease and other memory/cognitive disorders of the brain.  

Anew Medical is focused on commercializing several blockbuster biologic drugs whose patents have expired and have been proven by its corporate partner to be highly similar to the Genentech/Roche reference antibodies already on the market. These antibody products are referred to as “biosimilars” or “biogenerics”. The Company exclusively licensed portfolio consists of Roche/Genentech’s bevacizumab (anti-VEGF, Avastin®) and rituximab (anti-CD20, Mabthera® and Rituxan®). 

To Find out the inside Scoop on LEAS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

LEAS

On October 4 LEAS announced it has acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX” and “FOLFIRI” multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. 

“Some of these drugs have previously been the subject of drug shortages and rationing in the past, so ANEW being able to provide an alternative, high quality source of these product was important to us,” stated Dr. Shalom Hirschman, the Chief Medical Officer of the Company. He also added that, “Having a European manufacturing source for each of the five MA’s was also important to us.” 

Dr. Joseph Sinkule, the Founder and CEO of ANEW stated, “We will combine the oncology drugs and additional drug assets with a portfolio of biosimilar biologics also used in the treatment of cancer, and then grow the business with more additions to the portfolio. Initiating marketing and sales in Europe and then migrating the dossier to the US allows us time to build a reliable business franchise and gain name recognition both in Europe and then the US, the two major global pharmaceutical markets.” Dr. Sinkule went on to say, “Our pricing of these life-saving medicines is ‘Cost Plus’, meaning the cost to produce these goods and a small margin needed to sell and distribute the drugs. The prices of our products are, therefore, affordable even in this era of significantly increased energy prices in Europe. Our biosimilar biologics will have higher margins as we will invest in Phase 3 studies and market approval expenses for each of those agents, but the strategy is still straightforward.” 

ANEW’s generic drug division comprised of drugs and biologics complements its “high tech” division focused on gene therapies associated with neurodegenerative diseases like Alzheimer’s disease, cancer, and aging (longevity). 

https://twitter.com/Master_of_Coin1/status/1577364095115870217

 For more on LEAS Subscribe Right Now!

LEAS is an exciting story developing in small caps; trading at a tiny market valuation Anew Medical went public on November 1, 2021 via a reverse merger into Strategic Asset Leasing Inc. The stock is up big after the Company announced it has acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX” and “FOLFIRI” multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Dr. Joseph Sinkule, the Founder and CEO of ANEW stated, “We will combine the oncology drugs and additional drug assets with a portfolio of biosimilar biologics also used in the treatment of cancer, and then grow the business with more additions to the portfolio. Initiating marketing and sales in Europe and then migrating the dossier to the US allows us time to build a reliable business franchise and gain name recognition both in Europe and then the US, the two major global pharmaceutical markets.We will be updating on LEAS when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in LEAS either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.